中文 | English
Return
Total: 162 , 1/17
Show Home Prev Next End page: GO
MeSH:(Glucagon-Like Peptide 1)

1.Clinical Efficacy of Glucagon Like Peptide-1 (GLP-1) Analogues.

Hyun Ji CHUN ; Hyuk Sang KWON

Journal of Korean Diabetes 2013;14(3):125-127

2.New Therapeutics for Diabetes Using Incretin Hormone.

Seungjoon OH

Korean Journal of Medicine 2011;80(6):625-634

4.GLP-1 receptor activation effects the p38MAPK signal pathway in hepatic stellate cells.

Lingkang WU ; Youming LI ; Yingchao LIU ; Cuilan TANG ; Feng WU ; Liangliang SHI ; Keda LU

Chinese Journal of Hepatology 2015;23(2):130-133

5.Comparative study on anorexigenic effect of glucagon-like peptide-1 receptor agonists in rats.

Song WEN ; Thiquynhnga NGUYEN ; Wen-Ze XIAO ; Chao-Xun WANG ; Min GONG ; Jian-Lan JIN ; Li-Gang ZHOU

Acta Physiologica Sinica 2019;71(4):514-526

6.Injectable Therapy for Diabetes Mellitus: Glucagon-Like Peptide-1 Receptor Agonist

Inkuk LEE ; Eun Seok KANG

Journal of Korean Diabetes 2019;20(3):149-156

7.New Drugs for Obesity Treatment.

Won Jun KIM ; Chang Beom LEE

Korean Journal of Medicine 2016;90(2):121-126

8.Liraglutide prevents high glucose level induced insulinoma cells apoptosis by targeting autophagy.

Ze-fang CHEN ; Yan-bo LI ; Jun-yong HAN ; Jia-jing YIN ; Yang WANG ; Li-bo ZHU ; Guang-ying XIE

Chinese Medical Journal 2013;126(5):937-941

9.Understanding the Mechanism of Action and Clinical Implications of Anti-Obesity Drugs Recently Approved in Korea

Kyoung Kon KIM

Korean Journal of Family Medicine 2019;40(2):63-71

10.The Role of Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors in Reducing Cardiovascular Events in Patients with Type 2 Diabetes

Gwang Sil KIM ; Joong Hyun PARK ; Jong Chul WON

Endocrinology and Metabolism 2019;34(2):106-116

Sort by Result Analysis

Display Mode

Output Records




File Type





Total: 162 , 1/17 Show Home Prev Next End page: GO